Neutral Result With Novel Agent in Diabetic Cardiomyopathy
ATLANTA, GA — A multicenter controlled trial testing the ability of an aldose reductase inhibitor to stabilize early-stage asymptomatic diabetic cardiomyopathy missed its primary endpoint, researchers reported. But several signals of benefit support a …